Pain sensitivity and injury associated with three methods of disbudding goat kids: Cautery, cryosurgical and caustic paste.

Pain sensitivity and skull/brain injury associated with cautery, cryosurgical and caustic paste disbudding were evaluated in goat kids. Kids (reared for meat; n=280) were randomly assigned to one of four treatments (n=70 per treatment): (1) sham-handling (SHAM) or (2) cautery (CAUT), (3) cryosurgical (CRYO) or (4) caustic paste (CASP) disbudding. A pain sensitivity test was carried out 15min pre-treatment and 1h post-treatment. Skull/brain injury was assessed at post-mortem examination. Kids with evidence of injury to the skull/brain, as well as a random sample of kids (n=15 per treatment) without evidence of skull/brain injury, were selected for histological examination of brain tissue. Average daily gains (ADG) were calculated from body weight measurements taken 10min pre-treatment and then at 2, 7 and 14days post-treatment as a measure of the potential effects of pain or injury on growth. CASP and CRYO kids displayed higher pain sensitivity post-treatment than CAUT or SHAM kids, suggesting that they experienced more acute pain 1h post-treatment. One of 70 CAUT kids had a perforated skull, but there was no histological evidence of brain injury in this animal; a further nine CAUT kids exhibited hyperaemia of the skull. The other treatments did not result in injury to the skull/brain. There was no evidence of a difference in ADG across treatments. Caustic paste and cryosurgical disbudding resulted in greater acute pain sensitivity than cautery disbudding; however, cautery disbudding has the potential to cause skull injury if performed incorrectly.

The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus.

Thalidomide therapy has been shown to cause increases in body weight in patients with HIV and tuberculosis infections. To examine the nature of this weight gain and its immunological correlates in patients with HIV infection, we studied a cohort of 13 patients with minimally symptomatic HIV disease. Patients were admitted to the Rockefeller University General Clinical Research Center and maintained on strict isocaloric diets to achieve weight stabilization before a 14-day course of thalidomide treatment. Mean percentage weight increase was 3.6% on day 14 of thalidomide therapy (p = 0.002). Weight gain was associated with a reduction in mean daily urinary nitrogen excretion of 1.81 g (p = 0.017). Resting energy expenditure was unaffected by thalidomide. Body composition analysis suggested some extracellular fluid retention in the first week of thalidomide therapy, followed by an expansion of lean tissue mass during the second week. Remarkably, total lymphocyte counts and CD8+ T cell counts increased following treatment with the drug from 1578 +/- 185 to 2617 +/- 265 and from 938 +/- 146 to 1369 +/- 231, respectively. Modest increases in CD4+ T cell counts were also observed. Levels of circulating TNF-alpha were not elevated at baseline. A significant increase in mean plasma levels of soluble interleukin 2 receptor (sIL-2r), from 1918 +/- 250 to 3816 +/- 411 pg/ml (p = 0.0022), occurred in response to thalidomide, suggesting drug-induced immunological activation. In conclusion, thalidomide treatment of patients with HIV infection caused weight gain and lean tissue anabolism, even when caloric intake was kept constant. The nature of the association between thalidomide treatment-induced metabolic changes and the immunomodulatory effects of the drug has yet to be elucidated.

Adverse reactions to thalidomide in patients infected with human immunodeficiency virus.

Thalidomide is emerging as a useful agent in the management of several complications of disease due to human immunodeficiency virus (HIV). We conducted three prospective studies of 56 HIV-infected patients who were treated with thalidomide for 14-21 days; 24 (43%) of these patients discontinued therapy owing to adverse reactions. Cutaneous and/or febrile reactions were the most frequent toxicities, arising in 20 (36%) of the patients. These reactions occurred after a mean interval (+/-SD) of 10 +/- 3 days and were associated with significantly lower CD4 T lymphocyte counts in reactors than in nonreactors (median count, 52.5/mm3 vs. 242 cells/mm3, respectively; P = .009). Four of four rechallenged patients experienced accelerated hypersensitivity; hypotension occurred in one case. Although sedation was an almost universal side effect among the patients, it was moderate or severe in only seven (13%); constipation was moderate or severe in five (9%) of the patients. Severe neuropathic symptoms and mood changes were each noted in two (4%) of the 56 patients. We conclude that the increasing use of thalidomide to treat HIV-infected patients must be accompanied by recognition of the drug's increased potential for toxicity in this population.

900-nm Nd:Ti:LiNbO(3) waveguide laser.

We report what is to our knowledge the first laser operation of Nd(3+) -doped LiNbO(3) near 900 nm. An absorbed power threshold of 26 mW was obtained when the device was pumped at 814 nm. The design of the waveguide geometry to favor laser operation at this wavelength is demonstrated.

Beat-length measurement in directional couplers by thermo-optic modulation.

In integrated-optical directional couplers formed by two parallel waveguides we measure the difference Deltabeta = beta(even) - ss(odd) between the propagation constants of the supermodes. We couple them locally by heating a fine spot on one of the guides. When the spot is scanned along the coupler, the output power from one of the guides is found to vary periodically. The period of variation is the modal beat length Lambda = 2pi/Deltabeta. We demonstrate this technique with directional couplers fabricated by K-ion exchange in glass. Beat lengths in the range 0.6 -2.2 mm are measured with an accuracy of +/-0.3%.

Channel waveguide laser at 1 microm in Yb-indiffused LiNbO(3).

We report laser action in a Ti-diffused LiNbO(3) waveguide doped with trivalent Yb ions by thermal indiffusion. Lasing was observed at 1008, 1030, and 1060 nm with thresholds as low as 15-mW launched pump power. We reduced photorefractivity, which initially permitted only intermittent lasing, by annealing the sample in wet O(2). The annealed sample lased continuously in a cavity formed by high-ref lectivity mirrors; however, with a 7% output coupler the output power exhibited instabilities. The greatest value of the output power observed under these conditions was consistent with a slope efficiency of ~16% with respect to absorbed power.

Tunable coupled-cavity waveguide laser at room temperature in Nd-diffused Ti:LiNbO(3).

We report on a Y-junction channel waveguide laser, operating at room temperature, in Nd-diffused Ti:LiNbO(3). Pumping was performed with a cw Ti:A1(2)O(3) laser operating at 816 nm. With feedback provided only by the polished end faces of the device, a cw lasing threshold of ~39-mW launched pump power was obtained, with a slope efficiency of ~35%. Using 95% reflectivity mirrors at the waveguide ends, we reduced the lasing threshold to ~4 mW, with a slope efficiency of ~2.6%. Tuning of the lasing signal over a range of 2.3 nm around a center wavelength of 1092.7 nm was demonstrated, with a monolithically integrated phase modulator.